Kyle Kuvalanka

Biography

Kyle brings more than 20 years of management, financial and strategy experience in the biopharmaceutical industry. Prior to Syros, he served as Chief Business Officer and Principal Financial and Accounting Officer of Blueprint Medicines, where he built the business organization, secured the company’s first strategic collaboration and led the execution of the company’s initial public offering. Before joining Blueprint Medicines, Kyle spent more than a decade at Millennium: The Takeda Oncology Company, where he served in a variety of business leadership roles, including as vice president of business development and corporate strategy. In this role, he was a member of the global oncology management team and portfolio review committee and led the overall strategic planning process for the therapeutic area with annual revenues in excess of $2 billion and a broad pipeline of novel therapies. During his time at Millennium, Kyle also successfully identified and structured R&D and commercial-stage strategic business relationships and led the negotiations of multiple licensing and collaboration agreements. Earlier in his career at Millennium, he held leadership positions in finance and led the investor relations effort. Prior to Millennium, Kyle worked in strategy consulting for biopharmaceutical companies. He holds a B.A. from Wesleyan University and an MBA from the Wharton School of the University of Pennsylvania.  

Research Interest

Business